| Literature DB >> 30941793 |
Ofer Shamni1, Bruno Nebeling2, Hilbert Grievink1, Eyal Mishani1.
Abstract
Radiolabeled prostate-specific membrane antigen (PSMA) targeting PET-tracers have become desirable radiopharmaceuticals for the imaging of prostate cancer (PC). Recently, the PET radiotracer [18 F]PSMA-1007 was introduced as an alternative to [68 Ga]Ga-PSMA-11, for staging and diagnosing biochemically recurrent PC. We incorporated a one-step procedure for [18 F]PSMA-1007 radiosynthesis, using both Synthra RNplus and GE TRACERlab FxFN automated modules, in accordance with the recently described radiolabeling procedure. Although the adapted [18 F]PSMA-1007 synthesis resulted in repeatable radiochemical yields (55 ± 5%, NDC), suboptimal radiochemical purities of 87 ± 8% were obtained using both modules. As described here, modifications made to the radiolabeling and the solid-phase extraction purification steps reduced synthesis time to 32 minutes and improved radiochemical purity to 96.10%, using both modules, without shearing the radiochemical yield.Entities:
Keywords: PET; PSMA; [18F]PSMA-1007; fluorine-18; prostate cancer
Mesh:
Substances:
Year: 2019 PMID: 30941793 DOI: 10.1002/jlcr.3732
Source DB: PubMed Journal: J Labelled Comp Radiopharm ISSN: 0362-4803 Impact factor: 1.921